Psychedelic Stock Review Initiates Coverage on Ehave Inc.

MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Psychedelic Stock Review has initiated coverage.

“Ehave is about to release a number of digital information tools and services made to enhance the effectiveness and practicality of Psychedelic treatments, for both patients and the medical community,” stated Roland Rick Perry, editor of the Biotech and Psychedelic Stock Reviews. Adding, “In 2019 Ehave sold its Clinical Software Platform to Zyus Life Sciences a biopharmaceutical company that offers patients cannabinoid and other phyto-therapeutic medical solutions for $3.2 million.”

Ben Kaplan CEO of Ehave stated, “With the successful sale of the cannabis centric platform that contained components specifically designed to be used by medical cannabis patients to efficiently gather and verify patient-reported outcomes and experiences, evaluate treatment progress, enhance patient engagement and improve data modeling we transitioned the Company to providing these same patient reporting and monitoring services to the Psychedelic industry.”

One of the greatest hurdles faced by Psychedelic patients and clinicians is the lack of a clinical framework to provide effective and reliable dosing and administration regimes. The Ehave Platform can be seamlessly incorporated into clinical trial programs and be a valuable tool for the collection of high-quality data that can be shared with patients and clinicians to validate efficacy in Psychedelic-based treatments, further strengthening its broad adoption world-wide.

“The Ehave patient monitoring and reporting services are essential for Psychedelic treatment clinics and the industry as a whole,” stated Perry. “The opening of Ketamine clinics are moving at a rapid pace. While well tolerated and reported as extremely effective, this is a nascent practice and data needs to collected from thousands of patients currently being treated and the 10’s of thousands who are destined to be treated. With the aid of Ehave’s artificial intelligence, the data provided by a broad set of clinics, can fine tune the practice of administering Ketamine treatments with regards to dosage and treatment times, as well as any potential adverse events. We are excited to initiate coverage on Ehave just as they are about to launch their digital monitoring services.”   

Alfred Farrington II, Chief Information Officer of Ehave said, “Ehave is about to launch a suite of products that will give patients better control of their medical records that will improve their overall heath. Powered by AI and predictive medicine our services are designed to enhance the daily lives of patients without boundaries and world-wide. We expect our reporting and monitoring services will greatly contribute to the growth of Ketamine based treatments as well as other Psychedelics as they are approved.”

The Report can be found on the Psychedelic Stock Review website.

http://psychedelicstockreview.com/report-ehave-inc-ehvvf-our-favorite-ps...

Coming Initiatives:

KetaDash 0.1 – Ehave’s KetaDash connects mental health patients with highly skilled nurses to provide ketamine therapy under expert supervision.

MegaTeam [Desktop Version] - Ehave's MegaTeam assessment and rehabilitation products are built on established methodologies for the measurement of cognitive abilities.

Ninja Reflex [Mobile Version] – Ehave’s Ninja Reflex is a video game intervention for kids with neurodevelopmental disorders.

Ehave Health Records Dashboard (Powered by HealthWizz) - Ehave Dashboard provides Ehave's users with an easy and user-friendly retrieval and management of medical records, regardless of where the records are hosted. The HIPAA compliant, decentralized mobile platform enables patients to aggregate, organize and share personal medical health records securely and efficiently to anyone, anywhere in the world. The Ehave dashboard finally provides a solution to the serious and widely reported difficulty of patients retrieving their own personal health records.

Ehave Mental Health App by CoggApps – The Ehave Mental Health App by CoggApps is an AI-controlled mental health monitoring tool designed by an MD and PhD-qualified psychiatrist using diagnostic techniques approved by the American Psychiatric Association and the World Health Organization. The platform is based on Apple HealthKit and GoogleFit for data processing and background mental health monitoring.

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

Forward-Looking Statement Disclaimer

Institutional Analyst is compensated for providing research coverage for Ehave Inc., please the report for disclosure and disclaimer details.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.

Contact for Ehave

Media Inquiries: Gabe Rodriguez

Email: [email protected]

Investor Relations:

Email: [email protected]

Phone: (623) 261-9046